Literature DB >> 3108890

The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.

I C Kettelhut, W Fiers, A L Goldberg.   

Abstract

Tumor necrosis factor (TNF) is a macrophage product under active study as an anticancer drug. However, this agent can be very toxic and has been implicated in the pathogenesis of endotoxic shock. After intravenous injection of human recombinant TNF (4 micrograms/g), growing rats showed an unusual constellation of physiological responses, and all died within 2-4 hr. In 1 hr, TNF caused a sharp fall (2.5 degrees C) in body temperature and a large increase in plasma prostaglandin E2 levels. Blood glucose initially increased, but then a profound hypoglycemia developed by 2 hr. The TNF-treated animals also showed diarrhea, cyanosis, and a severe metabolic acidosis. A single injection of the cyclooxygenase inhibitors indomethacin or ibuprofen before the TNF treatment completely prevented the rapid killing and reduced eventual lethality by 70%. These agents blocked prostaglandin E2 production and prevented the hypothermia, changes in blood glucose, acidosis, and other symptoms. Since similar physiological changes have been reported after endotoxin injection, our data support the suggestion that TNF production is a critical factor in the development of septic shock. These findings also indicate that increased production of prostaglandins or thromboxanes is important in endotoxic shock and argue that cyclooxygenase inhibitors should be useful in its therapy. Indomethacin did not block the cytotoxic effects of TNF in vitro on several transformed cell lines (HeLa, Me 180, or L929). Therefore, combined use of TNF with a cyclooxygenase inhibitor may allow safer administration of high doses of this polypeptide to cancer patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108890      PMCID: PMC305067          DOI: 10.1073/pnas.84.12.4273

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia.

Authors:  F M Torti; B Dieckmann; B Beutler; A Cerami; G M Ringold
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

2.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

3.  Treatment of experimental canine endotoxin shock with ibuprofen, a cyclooxygenase inhibitor.

Authors:  P M Almqvist; M Kuenzig; S I Schwartz
Journal:  Circ Shock       Date:  1984

4.  Arachidonic acid induced release of insulin and glucagon: role of endogenous prostaglandins in pancreatic hormone secretion.

Authors:  R D Phair; S B Pek; W E Lands
Journal:  Diabete Metab       Date:  1984-05

5.  Molecular cloning of the complementary DNA for human tumor necrosis factor.

Authors:  A M Wang; A A Creasey; M B Ladner; L S Lin; J Strickler; J N Van Arsdell; R Yamamoto; D F Mark
Journal:  Science       Date:  1985-04-12       Impact factor: 47.728

Review 6.  Monokines and the metabolic pathophysiology of septic shock.

Authors:  J P Filkins
Journal:  Fed Proc       Date:  1985-02

7.  Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor.

Authors:  T Shirai; H Yamaguchi; H Ito; C W Todd; R B Wallace
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

8.  Persistent hyperinsulinemia due to induced euglycemia in awake endotoxic minipigs.

Authors:  M S Hand; M J Fettman; L G Chandrasena; J L Cleek; R A Mason; R W Phillips
Journal:  Circ Shock       Date:  1984

9.  Reticuloendothelial system function and glucose-insulin dyshomeostasis in sepsis.

Authors:  J P Filkins
Journal:  Am J Emerg Med       Date:  1984-01       Impact factor: 2.469

10.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.

Authors:  B Beutler; J Mahoney; N Le Trang; P Pekala; A Cerami
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  73 in total

1.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.

Authors:  F D Pagani; L S Baker; C Hsi; M Knox; M P Fink; M S Visner
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 2.  The role of mediators in the response to thermal injury.

Authors:  Y K Youn; C LaLonde; R Demling
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

3.  Effects of recombinant monokines on hepatic pyruvate dehydrogenase, pyruvate dehydrogenase kinase, lipogenesis de novo and plasma triacylglycerols. Abolition by prior fasting.

Authors:  M Blackham; D Cesar; O J Park; T C Vary; K Wu; S Kaempfer; C H Shackleton; M K Hellerstein
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

Review 4.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

5.  The diverse roles of the TNF axis in cancer progression and metastasis.

Authors:  Boram Ham; Maria Celia Fernandez; Zarina D'Costa; Pnina Brodt
Journal:  Trends Cancer Res       Date:  2016-01-01

6.  Tumor necrosis factor alpha and the anemia associated with murine malaria.

Authors:  K L Miller; P H Silverman; B Kullgren; L J Mahlmann
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

Review 7.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

8.  Induction of circulating tumor necrosis factor cannot be demonstrated during septicemic salmonellosis in calves.

Authors:  J E Peel; M J Voirol; C Kolly; D Gobet; S Martinod
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

9.  Hypoglycemia, hormones and cytokines in fatal meningococcal septicemia.

Authors:  J A Romijn; M H Godfried; C Wortel; H P Sauerwein
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

10.  Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease.

Authors:  T Moritz; N Niederle; J Baumann; D May; E Kurschel; R Osieka; J Kempeni; E Schlick; C G Schmidt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.